组蛋白赖氨酸甲基化修饰与先天性心脏病研究进展

doi:10.3724/SP.J.1005.2010.00650

遗传 ›› 2010, Vol. 32 ›› Issue (7): 650-655.doi: 10.3724/SP.J.1005.2010.00650

组蛋白赖氨酸甲基化修饰与先天性心脏病研究进展

盛伟1, 2, 马端1

1. 复旦大学上海医学院分子医学教育部重点实验室, 复旦大学出生缺陷研究中心, 上海 200053; 2. 安徽科技学院生命科学学院, 凤阳 200032

收稿日期:2009-10-28 修回日期:2010-01-12 出版日期:2010-07-20 发布日期:2010-07-20
通讯作者: 马端 E-mail:duanma@shmu.edu.cn
基金资助:
国家重点基础研究发展规划(973计划)项目(编号：2009CB941704)资助

Research progress in modification of histone lysine methylation and congenital heart defect

SHENG Wei^{1, 2}, MA Duan¹

1. Key Laboratory of Molecular Medicine, Ministry of Education,Shanghai Medical College, Fudan University, Birth Defects Research Center, Fudan University, Shanghai 200053, China; 2. College of Life Science, Anhui Science and Technology University, Fengyang 200032, China

Received:2009-10-28 Revised:2010-01-12 Online:2010-07-20 Published:2010-07-20
Contact: MA Duan E-mail:duanma@shmu.edu.cn

摘要/Abstract

摘要： 组蛋白修饰是表观遗传调控的一个重要组成部分, 它通过改变染色质的结构以及与其他调控蛋白相互作用, 调节真核基因的表达。组蛋白修饰异常可能导致多种疾病的发生, 同时, 组蛋白修饰的可逆性为疾病的治疗提供了新的思路。文章主要对组蛋白赖氨酸甲基化修饰与先天性心脏病发生的有关机制进行了综述, 以期能够为从事该领域研究的科研人员提供有价值的参考。

关键词: 表观遗传调控, 蛋白甲基化, 天性心脏病

Abstract: Histone modification is an important component of epigenetic regulation, which can regulate eukaryotic gene expression by changing the structure of chromatin and interacting with other regulatory proteins. Abnormal histone modifications may lead to a variety of diseases, while the reversibility of histone modification provides a new way of thinking for treatment of these diseases. In this paper, we discussed the mechanism of histone lysine methylation related to congenital heart defect in order to provide a useful reference for researchers working in this area.

Key words: epigenetic regulation, istone methylation, ongenital heart defect

盛伟，马端. 组蛋白赖氨酸甲基化修饰与先天性心脏病研究进展[J]. 遗传, 2010, 32(7): 650-655.

CHENG Wei, MA Duan. Research progress in modification of histone lysine methylation and congenital heart defect[J]. HEREDITAS, 2010, 32(7): 650-655.

参考文献

[1] Kaminsky ZA, Tang T, Wang S-C, Ptak C, Oh GHT, Wong AHC, Feldcamp LA, Virtanen C, Halfvarson J, Tysk C, McRae AF, Visscher PM, Montgomery GW, Gottesman II, Martin NG, Petronis A. DNA methylation profiles in monozygotic and dizygotic twins. Nat Genet, 2009, 41(2): 240–245. [2] Kouzarides T. Chromatin modifications and their function. Cell, 2007, 128(4): 693–705. [3] Sims III1 RJ, Nishioka K, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet, 2003, 19(11): 629–638. [4] Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature, 2000, 406(6796): 593–599. [5] Van Leeuwen F, Gafken PR, Gottschling DE. Dot1p modulates silencing in yeast by methylation of the nu-cleosome core. Cell, 2002, 109(6): 745–756. [6] Shi Y, Whetstine JR. Dynamic regulation of histone lysine methylation by demethylases. Mol Cell, 2007, 25(1): 1–14. [7] Klose RJ, Zhang Y. Regulation of histone methylation by demethylimination and demethylation. Nat Rev Mol Cell Biol, 2007, 8(4): 307–318. [8] Swigut T, Wysocka1 J. H3K27 demethylases, at long last. Cell, 2007, 131(1): 29–32. [9] Laribee RN, Krogan NJ, Xiao T, Shibata Y, Hughes TR, Greenblatt JF, Strahl BD. BUR kinase selectively regulates H3-K4 trimethylation and H2B ubiquitylation through re-cruitment of the PAF elongation complex. Curr Biol, 2005, 15(16): 1487–1493. [10] Tan XG, Rotllan J, Li HQ, DeDeyne P, Du SJ. SmyD1, a histone methyltransferase, is required for myofibril organization and muscle contraction in zebrafish embryos. Proc Natl Acad Sci USA, 2006, 8(103): 2713–2718. [11] Fulcoli FG, Huynh T, Scambler PJ, Baldini A. Tbx1 regulates the BMP-Smad1 pathway in a transcription independent manner. PLoS ONE, 2009, 4(6): 1371–1384. [12] Miller SA, Huang AC, Miazgowicz MM, Brassil MM, Weinmann AS. Coordinated but physically separable interac-tion with H3K27-demethylase and H3K4-methyltransferase activities are required for T-box protein-mediated activa-tion of developmental gene expression. Genes Dev, 2008, 22(21): 2980–2993. [13] Lange M, Kaynak B, Forster UB, Tönjes M, Fischer JJ, Grimm C, Schlesinger J, Just S, Dunkel I, Krueger T, Mebus S, Lehrach H, Lurz R, Gobom J, Rottbauer W, Abdelilah-Seyfried S, Sperling S. Regulation of muscle development by DPF3, a novel histone acetylation and methylation reader of the BAFchromatin remodeling complex. Genes Dev, 2008, 22(17): 2370–2384. [14] Stow LR, Gumz ML, Lynch IJ, Greenlee MM, Rudin A, Cain BD, Wingo CS. Aldosterone modulates steroid re-ceptor binding to the endothelin-1 gene (Edn 1). J Biol Chem, 2009, 284(44): 1–20. [15] Fan ZP, Yamaza T, Lee JS. BCOR regulates mesenchymal stem cell function by epigenetic mechanisms. Nat Cell Biol, 2009, 11(8): 1002–1010. [16] Nakayama J, Rice JC, Strahl BD, Allis CD, Grewal SI. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science, 2001, 292(5514): 110–113. [17] Stewart DR, Kleefstra T. The chromosome 9q subtelomere deletion syndrome. Am J Med Genet Part C (Seminars Med Genet), 2007, 145(4): 383–392. [18] Kleefstra T, Brunner HG, Amiel J. Loss-of-function mutations in euchromatin histone methyl transferase 1 (EHMT1) cause the 9q34 subtelomeric deletion syndrome. Am J Human Genet, 2006, 79(2): 370–378. [19] Bikoff EK, Morgan MA, Robertson EJ. An expanding job description for Blimp-1/PRDM1. Genet Dev, 2009, 19(4): 1–7. [20] Lee Y, Song AJ, Baker R, Micales B. Jumonji, a nuclear protein that is necessaryfor normal heart development. Circ Res, 2000, 86(9): 932–938. [21] Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease. Genes Dev, 2008, 22(9): 1115–1140. [22] Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev, 2006, 20(9): 1123–1136. [23] Weston AD, Ozolins TRS, Brown NA. Thoracic skeletal defects and cardiac malformations: A common epigenetic link? Birth Defects Res (Part C), 2006, 78(4): 354–370. [24] Jepsen K, Gleiberman AS, Shi C, Simon DI, Rosenfeld MG. Cooperative regulation in development by SMRT and FOXP1. Genes Dev, 2008, 22(6): 740–745. [25] Jepsen K, Solum D, Zhou TY, McEvilly RJ, Kim H-J, Glass CK, Hermanson O, Rosenfeld MG. SMRT-mediated repression of an H3K27 demethylasein progression from neural stem cell to neuron. Nature, 2007, 450(期): 415–420. [26] Bannister AJ, Schneider R, Myers FA, Thorne AW, Crane-Robinson C, Kouzarides T. Spatial distribution of di- and tri-methyl lysine 36 of histone H3 at active genes. J Biol Chem, 2005, 280(18): 17732–17736. [27] Krogan NJ, Kim M, Tong A, Golshani A, Cagney G, Canadien V, Richards DP, Beattie BK, Emili A, Boone C, Shilatifard A, Buratowski S, Greenblatt J. Methyla-tion of histone H3 by Set2 in Saccharomyces cerevisiae is linked to transcriptional elongation by RNA polymerase II. Mol Cell Biol, 2003, 23(12): 4207–4218. [28] Nimura K, Ura K, Shiratori H, Ikawa M, Okabe M, Schwartz RJ, Kaneda Y. A histone H3 lysine 36 trimethyl-transferase links Nkx2-5 to Wolf–Hirschhorn syndrome. Nature, 2009, 460(7252): 287–292. [29] Frederiks F, Tzouros M, Oudgenoeg G. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. Nat Struct Mol Biol, 2008, 15(6): 550–557. [30] Barry ER, Krueger W, Jakuba CM. ES Cell cycle progression and differentiation require the action of the histone methyl-transferase Dot1L. Stem Cell, 2009, 27(7): 1538–1547. [31] Illi B, Scopece A, Nanni S, Farsetti S, Morgante L, Big-lioli P, Capogrossi MC, Gaetano C. Epigenetic histone modification and cardiovascular lineage programming in mouse embryonic stem cells exposed to laminar shear stress. Circ Res, 2005, 3(18): 501–508. [32] Lennartsson A, Ekwall K. Histone modification patterns and epigenetic codes. Biochim Biophys Acta, 2009, 1790(9): 863–868. [33] Tatton-Brown K, Rahman N. Clinical features of NSD1-positive soto syndrome. Clin Dysmorphol, 2004, 13(4): 199–204. [34] Rayasam GV, Wendling Q, Angrand PO, Mark M, Niederreither K, Song LY, Lerouge T, Hager GL, Chambon P, Losson R. NSD1 is essential for early post-implantation development and has a catalytically ac-tive SET domain. EMBO J, 2003, 22(12): 3153–3163.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号
总访问:,今日访问:,当前在线:

组蛋白赖氨酸甲基化修饰与先天性心脏病研究进展

Research progress in modification of histone lysine methylation and congenital heart defect

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 11

编辑推荐

Metrics

[1]	王建, 张凯翔, 芦国珍, 赵湘辉. 5-羟甲基胞嘧啶及其TET氧合酶在神经系统发育和相关疾病中的研究进展[J]. 遗传, 2017, 39(12): 1138-1149.
[2]	崔婷婷, 邢天宇, 褚衍凯, 李辉, 王宁. PPARγ在脂肪生成中的遗传和表观遗传调控[J]. 遗传, 2017, 39(11): 1066-1077.
[3]	欧阳平,刘远航,黄志刚,齐小娟,倪倩,刘亚萍,宋仁生,李涛,吴柱国. tRNA抑制子对转录因子NKX2.5提前终止密码子的通读[J]. 遗传, 2015, 37(4): 367-373.
[4]	李芬, 杨敬辉, 吴秀丽, 张卫林, 王冠峰, 岳晓杰. 酿酒酵母组蛋白H3 K4L和K36L突变对细胞生长和GAL1、SSA3、PHO5表达的影响[J]. 遗传, 2014, 36(8): 827-834.
[5]	葛少钦，李建忠，张晓静. 精子发生过程中组蛋白甲基化和乙酰化[J]. 遗传, 2011, 33(9): 939-946.
[6]	宋博研，朱卫国. 组蛋白甲基化修饰效应分子的研究进展[J]. 遗传, 2011, 33(4): 285-292.
[7]	冯碧薇，陈建强，雷秉坤，潘贤，吕红. 酵母模式生物研究表观遗传调控基因组稳定性的进展[J]. 遗传, 2010, 32(8): 799-807.
[8]	辛娜，邱广蓉，宫立国，徐小延，孙开来. 单纯性先天性心脏病中TBX5基因表达异常的机制[J]. 遗传, 2009, 31(4): 374-374―380.
[9]	高文龙，刘红林. DOT1—— 一类新的组蛋白赖氨酸甲基转移酶[J]. 遗传, 2007, 29(12): 1449-1454.
[10]	杜玉荣，杨焕杰，谭震，黄昀，李树林，田家伟，张贵寅，李璞，傅松滨. 22q11微缺失与先天性心脏病的关系的研究[J]. 遗传, 2005, 27(6): 873-876.
[11]	李想，张飞雄. 关于组蛋白甲基化的研究[J]. 遗传, 2004, 26(2): 244-248.